CRS has just closed its best month in years, up 31% to $616.84, yet the consensus price target still trails the stock by a wide margin — a gap that now defines the entire setup heading into July earnings.
The analyst story is the most striking tension this week. Keybanc moved the most dramatically, lifting its target from $459 to $644 on June 30 while keeping its Overweight rating — the first target on the Street to actually clear the current price. That move stands in sharp contrast to the broader analyst pack, which remains clustered well below where the stock trades: the consensus mean sits at $489, roughly 20% below $616. JP Morgan, TD Cowen, Susquehanna, and BTIG all raised targets after the April earnings beat, but every one of those upgrades is now underwater relative to the share price. The Street has been directionally right on CRS all year — it has consistently rated the stock positively — but the magnitude of the rally has left targets looking stale almost as fast as they get filed. Wells Fargo's Equal-Weight is the sole holdout among the recent movers, with a $425 target that now sits roughly 30% below market. Bulls point to structural demand from aerospace and defense, strong margin expansion in niche superalloys, and balance sheet discipline. Bears flag capex slippage and question whether a P/E above 51x and a P/B near 12x are sustainable for an industrial materials company, however specialized.
Positioning in the lending market is relaxed, and that tells its own story. Borrow availability is extremely loose — around 2,837% of short interest, meaning there are roughly 28 shares available to lend for every one already borrowed. That level is comfortably within normal ranges for CRS, well above the 52-week tightest reading of 478%. Borrowing costs are negligible at 0.48%, actually down 15% on the week despite edging higher in the most recent session. Short interest itself has climbed about 10% over the past week to 3.9% of free float — notable directionally, but not a crowded position by any measure. The ORTEX short score of 36 and a short score rank in the 40th percentile both point in the same direction: bears are incrementally more active, but there is no conviction buildup. Options lean modestly defensive, with the put/call ratio at 0.62 — above its 20-day average of 0.53 by just over one standard deviation — but nothing approaching the kind of hedging pressure that would signal real concern ahead of the July 30 earnings date.
One ownership detail is worth noting. The 90-day insider net is marginally positive in share terms at around 14,800 shares, but the recent activity is entirely on the sell side. The Chief Commercial Officer sold roughly 11,800 shares across multiple transactions on May 5, averaging around $441, and a director trimmed another 2,000 shares at $488 on June 1. Both sold well below the current price — the stock has since run a further 25-40% past those exit levels. That kind of selling ahead of a major move is more routine than alarming, but it does mean that the insiders who know the business best were reducing exposure during the same period the stock was breaking out.
After the April 30 print, CRS gained 5.6% the next day and extended that to nearly 10% over the following week. The setup for July 30 is therefore not about whether the aerospace cycle is intact — the Street broadly agrees it is — but whether Q3 guidance can justify a P/E that has expanded nearly 10 points in a single month.
See the live data behind this article on ORTEX.
Open CRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
